Spero Therapeutics (NASDAQ:SPRO) Stock Passes Below 200 Day Moving Average – What’s Next?

Spero Therapeutics, Inc. (NASDAQ:SPRO)’s share price crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $1.23 and traded as low as $0.85. Spero Therapeutics shares last traded at $0.91, with a volume of 371,185 shares changing hands.

Wall Street Analyst Weigh In

Several brokerages have issued reports on SPRO. TD Cowen restated a “hold” rating on shares of Spero Therapeutics in a research report on Monday, November 18th. HC Wainwright restated a “buy” rating and issued a $5.00 price target on shares of Spero Therapeutics in a research note on Monday, December 2nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research report on Friday, November 15th. Finally, Evercore ISI cut shares of Spero Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research report on Friday, December 20th.

Spero Therapeutics Trading Down 2.4 %

The firm has a market capitalization of $47.65 million, a price-to-earnings ratio of 12.49 and a beta of 0.63. The stock’s 50-day moving average is $1.07 and its 200-day moving average is $1.23.

Hedge Funds Weigh In On Spero Therapeutics

An institutional investor recently raised its position in Spero Therapeutics stock. Renaissance Technologies LLC boosted its holdings in Spero Therapeutics, Inc. (NASDAQ:SPRO) by 14.2% in the second quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 975,952 shares of the company’s stock after purchasing an additional 121,492 shares during the quarter. Renaissance Technologies LLC owned about 1.81% of Spero Therapeutics worth $1,269,000 at the end of the most recent quarter. Institutional investors own 25.60% of the company’s stock.

Spero Therapeutics Company Profile

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease.